SC
BSX icon

Scholtz & Company’s Boston Scientific BSX Stock Holding History

Scholtz & Company’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.01M Buy
+47,957
New +$3.84M 1.54% 32

Other funds holding BSX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Scholtz & Company's BSX Position: Q1 2026 in Review

Scholtz & Company opened a new position in Boston Scientific (BSX) in Q1 2026: 47,957 shares worth $3.01M. The stake represents 1.54% of the portfolio and ranks #32 among its holdings.

1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Scholtz & Company held 47,957 shares of Boston Scientific worth $3.01M as of Q1 2026.
  • Boston Scientific was a new Scholtz & Company position in Q1 2026.
  • Boston Scientific made up 1.54% of Scholtz & Company's portfolio in Q1 2026, its #32 holding.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Scholtz & Company's 13F filing for Q1 2026, filed 15 May 2026.